Sign inJoin waitlistJoin the waitlist

Steven Willi

Director, Diabetes Center for Children · Children's Hospital of Philadelphia

Credentials: · ·

History

Diabetes Center for Children · Children's Hospital of Philadelphia
Present
Children's Hospital of Philadelphia
Present

Pediatric Endocrinology
Children's Hospital of Philadelphia
1988–1991
Pediatrics
Children's Hospital of Philadelphia
1985–1988
Johns Hopkins Univ Sch of Med
1981–1985

Research

Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes
New England Journal of Medicine · 2010 · 623 citations
Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical Trial
JAMA · 2020 · 345 citations
Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline
The Journal of Clinical Endocrinology & Metabolism · 2011 · 344 citations

WT
William Tamborlane
15 papers · 2 as a resident
Linda DiMeglio
12 papers
Colin Hawkes
11 papers
Georgeanna Klingensmith
10 papers
Stephen Gitelman
10 papers
Fida Bacha
9 papers
Lori Laffel
9 papers
Jamie Wood
7 papers
John Buse
7 papers
Peter Gottlieb
7 papers
Roshanak Monzavi
6 papers
Wayne Moore
6 papers

Grants

Career Development Program in Pediatric Diabetes Research (K12) at CHOP
National Institute of Diabetes and Digestive and Kidney Diseases · K12
Contact PI · $3.6M · Children's Hosp of Philadelphia
2011–2022
Safety & Efficacy of Atorvastatin in Newly Diagnosed Type 1 Diabetes
Food and Drug Administration · R01
Contact PI · $565.5K · Children's Hosp of Philadelphia
2007–2011
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $201.5K · Medical University of South Carolina
1997–1999
Carnitine and Coa Pyruvate Dehydrogenase Activity
National Institute of Diabetes and Digestive and Kidney Diseases · F32
Contact PI · $65.6K · Children's Hosp of Philadelphia
1991

Clinical trials

Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)
Principal investigator · Completed · Phase 2
Children's Hospital of Philadelphia
2007–2013
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2026–2028
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2026–2031
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2027